Questions Raised About Invokana Label Expansion For CV Risk Reduction

It hasn’t received a lot of media attention but on Tuesday the FDA approved an expansion of the canagliflozin (Invokana, Janssen) label to include a reduction in the risk of heart attack, stroke, or CV death in adults with type 2 diabetes and established CV disease. Canagliflozin, an oral SGLT2 inhibitor, thus becomes the third...Click here to continue reading...

Source: CardioBrief - November 1, 2018 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics CVOT Invokana Source Type: blogs